|
||||||||||||||||||||||
|
|
Alternate Title Phase II Study of HLA-Matched Nonmyeloablative Peripheral Blood Stem Cell Transplantation Followed By Allogeneic T-Cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
Special Category: NIH Clinical Center trial Trial Description Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. The donated stem cells may replace the patient’s immune cells and help destroy any remaining tumor cells (graft-versus-tumor effect). Giving an infusion of the donor’s T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine with or without mycophenolate mofetil or methotrexate after the transplant may stop this from happening. This phase II trial is studying how well peripheral stem cell transplant works in treating patients with metastatic kidney cancer. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will receive chemotherapy during a 7-day period. On day 8, they will undergo peripheral stem cell transplant. Treatment with stem cells may be repeated on days 9 and 10. Patients will also receive cyclosporine beginning 4 days before the transplant and continuing for up to approximately 3 months. Some patients may also receive mycophenolate mofetil or methotrexate. Some patients may receive infusions of donated T cells. Patients will be evaluated every 2 months for 6 months, every 3 months for 2 years, and every 6 months until year 5. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations National Heart, Lung, and Blood Institute
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |